Medicinova Inc Dossier
Qualitative Analysis
Business overview
MediciNova, Inc. is a clinical-stage biopharmaceutical company founded in 2000 and headquartered in La Jolla, California. The company focuses on acquiring and developing novel, small-molecule therapeutics for serious diseases with high unmet medical needs, primarily targeting inflammatory, fibrotic, and neurodegenerative disorders. MediciNova's development strategy centers on two lead clinical compounds: MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent, and MN-001 (tipelukast), an orally bioavailable compound targeting fibrotic and metabolic disorders. The company utilizes a capital-efficient model, leveraging investigator-sponsored trials, government-funded studies, and strategic partnerships to advance its pipeline while maintaining a low operating cash burn.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing lead candidate MN-166 (ibudilast) through late-stage clinical trials for neurodegenerative diseases, specifically ALS (COMBAT-ALS Phase 2b/3 trial) and degenerative cervical myelopathy (DCM), alongside investigator-initiated and grant-funded trials for glioblastoma, Long COVID, and substance use disorders.
Expected impact: Establish clinical efficacy and safety to support regulatory submissions and potential commercialization.
Running a large-scale Expanded Access Program for ALS patients to provide broader access to MN-166 (ibudilast) while collecting real-world safety and efficacy data.
Expected impact: Broadens patient access and strengthens the clinical evidence base supporting regulatory approval efforts.
Developing MN-001 (tipelukast) for hypertriglyceridemia, non-alcoholic fatty liver disease (NAFLD/MAFLD), and Type 2 diabetes.
Expected impact: Expand pipeline indications into high-value metabolic and fibrotic disease markets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Repurposing MN-166 as a potential medical countermeasure against chlorine gas-induced lung damage, such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).
Terms: BARDA funds the proof-of-concept studies in preclinical models.
Licensing and development partnership for key pipeline compounds.
Terms: Subject to milestone payments and royalties on future sales.
Licensing and development partnership for key pipeline compounds.
Terms: Subject to milestone payments and royalties on future sales.